New drugs and targeted treatments in Hodgkin's lymphoma

Cancer Treatment Reviews

Volumn 40, Issue 3, 2014, Pages 457-464

  Provencio, Mariano ^a   Sánchez, Antonio ^a   Sánchez Beato, Margarita ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Bendamustine; Brentuximab vedotin; Deacetylase inhibitors; Hodgkin's lymphoma; Lenalidomide; M TOR inhibitors; Target treatments

Indexed keywords

BENDAMUSTINE; BRENTUXIMAB VEDOTIN; LENALIDOMIDE; NEW DRUG; PANOBINOSTAT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE COURSE; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; NONHUMAN; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

BENDAMUSTINE; BRENTUXIMAB VEDOTIN; DEACETYLASE INHIBITORS; HODGKIN'S LYMPHOMA; LENALIDOMIDE; M-TOR INHIBITORS; TARGET TREATMENTS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; HODGKIN DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84892859142     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.09.005     Document Type: Review

References (75)

1. Canellos G.P. Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma - can they make one of medical oncology's chemotherapy success stories more successful?. J Clin Oncol 2012, 18:2171-2172.
2. De Vita V.T., Simon R.M., Hubbard S.M. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587-595.
3. Bonadonna G., Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982, 9:21-35.
4. Piccaluga P.P., Agostinelli C., Gazzola A., et al. Pathobiology of Hodgkin lymphoma. Adv Hematol 2011, 10.1155/2011/920898.
5. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072.
6. Falini B., Pileri S., Pizzolo G., et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor superfamily as a tool for diagnosis and immunotherapy. Blood 1995, 85:1-14.
7. Chiarle R., Podda A., Prolla G., et al. CD 30 in normal and neoplastic cells. Clin Immunol 1999, 90:157-164.
8. Farrel K., Jarret R.F. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011, 58:15-25.
9. Walh A.F., Klussman K., Thompson J.D., et al. The anti-CD30 monoclonal antibody SNG-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2012, 62:3736-3742.
10. Forero-Torres A., Leonard J.P., Younes A., et al. A phase II study of SNG-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171-179.
11. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764-2769.
12. Blum K.A., Jung S.H., Johnson J.L., et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc-RIIIa-158 V/F polymorphism. Ann Oncol 2010, 21:2246-2254.
13. Doronina S.O., Bovee T.D., Meyer D.W., et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 2008, 19:1960-1963.
14. Ansell S.M. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs 2011, 20:99-105.
15. Oflazoglu E., Kissler K.M., Sievers E.L., et al. Combination of the anti-CD30-auristation-E antibody-drug conjugate (SNG-35) with chemotherapy improves antitumor activity in Hodgkin lymphoma. Br J Haematol 2008, 142:69-73.
16. Younes A., Barlett L., Leonard J.P., et al. Brentuximab vedotin (SNG-35) for relapsed CD30 -positive lymphomas. N Engl J Med 2010, 363:1812-1821.
17. Fanale M.A., Forero-Torres A., Rosenblatt J.D., et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractor CD 30-positive hematologic malignancies. Clin Cancer Res 2012, 18:248-255.
18. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
19. Swain S.M., Arezzo J.C. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008, 6:455-467.
20. De Claro A., McGinn K., Kwitkowski V., et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012, 18:5845-5849.
21. Anagnostopoulos I., Hansmann M.L., Franssila K., et al. European Task Force on lymphoma Project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with nodular growth pattern and abundant lymphocytes. Blood 2000, 96:1889-1899.
22. Sarina B., Castagna L., Farian L., et al. Allogenic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010, 115:3671-3677.
23. Theurich S., Malcher J., Wennhold K., et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2012, [Epub ahead of print].
24. Ram R., Gooley T.A., Maloney D.G., et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogenic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1537-1545.
25. Wudhikarn K., Brunstein C.G., Bachanova V., et al. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant 2011, 17:1497-1504.
26. Gopal A.K., Ramchandren R., O'Connor O.A., et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogenic stem cell transplantation. Blood 2012, 120:560-568.
27. Ansell S.M., Connors J.M., Park S.I., O'Meara M.M., Younes A. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. ASH Ann Meeting Abstr 2012, 120:798.
28. ClinicalTrials.gov.: a phase 3 study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma following stem cell transplant (the AETHERA trial). Accessed December 4, 2012. http://www.clinicaltrials.gov/ct2/show/NCT01100502.
29. US Food and Drug Administration. FDA drug safety communication: new boxed warning and contraindication for Adcetris (brentuximab vedotin), January 13, 2012. Accessed December 10, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm287668.htm.
30. Rodríguez Dorantes M., Téllez N., Cerbón M.A., et al. Metilación del ADN: un fenómeno epigenético de importancia médica. Rev Invest Clin 2004, 56:56-71.
31. Buglio D., Younes A. Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs 2012, 28(Suppl. 1):S21-S27.
32. Oki Y., Copeland A., Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 2011, 4:245-252.
33. a and VEGF, and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood ASH Ann Meet Abstr 2012, 116:2851.
34. Buglio D., Georgakis G.V., Hanabuchi S., et al. Vorinostat inhibits STAT6-mediated YH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
35. Jona A., Khaskhely N., Buglio D., et al. The histone deacetylase inhibitor entinostat (SNDX-275) targets Hodgkin lymphoma through a dual mechanism of immune modulation and apoptosis induction. Blood ASH Ann Meet Abstr 2010, 116:2850.
36. Kewitz S., Bernig T., Staege M.S. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells. Leuk Res 2012, 36:773-778.
37. Buglio D., Georgakis G.V., Hanabuchi S., et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
38. Younes A., Sureda A., Ben-Yehuda D., et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012, 30:2197-2203.
39. Lemoine M., Derenzini E., Buglio D., et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012, 119:4017-4025.
40. Kirschbaum M.H., Goldman B.H., Zain J.M., et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012, 53:259-262.
41. Younes A., Oki Y., Bociek R.G., et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011, 12:1222-1228.
42. Jóna A., Khaskhely N., Buglio D., et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol 2011, 39:1007-1017.
43. Younes A., Hernandez F., Bociek R.G., et al. ENGAGE-501: phase 2 study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL), interim results. Blood ASH Ann Meet Abstr 2010, 116:3959.
44. Forero-Torres A., Saleh M.N. Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War. Clin Lymphoma Myeloma 2007, 8(Suppl. 1):S13-S17.
45. Kath R., Blumenstengel K., Fricke H.J., et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001, 127:48-54.
46. Ruffert K., Jahn H., Syrbe G., et al. Bendamustin as an alternative approach to treat malignant non-Hodgkin's lymphoma. Z Klin Med 1989, 8:671-674.
47. Borchmann P., Schnell R., Dielh V., et al. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998, 9(Suppl. 5):S103-S108.
48. Herold M., Keinert K., Anger G. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's disease. Onkologie 1992, 15:501-505.
49. Gandhi W. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Sem Oncol 2002, 29:4-11.
50. Moskowitz A.J., Hamlin P.A., Perales M.A., et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2012, 10.1200/JCO.2012.45.3308.
51. Corazzelli G., Angilli F., DÁrco A., et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2012, 10.1111/bjh.12120.
52. Anastasia A., Carlo-Stella C., Corradini P., et al. Bendamustine for relapsed/refractory classical Hodgkin lymphoma after high dose chemotherapy and/or allogeneic transplant: a study of Fondazione Italiana Linfomi (FIL). Blood ASH Ann Meeting 2012, 120:3652.
53. Leoni L.M., Hartely J.A. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Sem Hematol 2001, 48(Suppl. 1):S1-S23.
54. Aldinucci D., Gloghini A., Pinto A., et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221:248-263.
55. Steidl C., Connors J.M., Gayscoyne R.D. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011, 29:1812-1826.
56. Fehniger T.A., Larson S., Trinkaus K., et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011, 118:5119-5125.
57. Kotla V., Goel S., Nischal S., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2(36):36.
58. Steidl C., Lee T., Shah S.P., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
59. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
60. Niens M., Visser L., Nolte I.M., et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008, 140:527-536.
61. Weihrauch M.R., Manzke O., Beyer M., et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005, 65:5516-5519.
62. Corazzelli G., De Filippi R., Capobianco G., et al. Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol 2010, 85:87-90.
63. Böll B., Borchmann P., Topp M.S., et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010, 148:480-482.
64. Mandac I., Kolonic S.O. Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma. J Hematol Oncol 2010, 10.1186/1756-8722-3-20.
65. Johnston P.B., Inwards D.J., Colgan J.P., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010, 85:320-324.
66. Johnston P.B., Pinter-Brown L., Rogerio J., et al. Open-label, single-arm, Phase II study of everolimus in patients with relapsed/refractory classical Hodgkin lymphoma. Blood ASH Ann Meet Abstr 2011, 118:2717.
67. Ibeas P., Cantos B., Provencio M. M-TOR inhibitor in the treatment of Hodgkin's lymphoma: a case report. Blood Lymph Cancer Targets Therapy 2001, 1:19-22.
68. Locatelli S., Giacomini A., Guidetti A., et al. Preclinical rationale for the use of the combined treatment with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in Hodgkin lymphoma. Blood ASH Ann Meet Abstr 2011, 118:1653.
69. Shabbir M., Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs 2010, 19:427-436.
70. Hexner E.O., Serdikoff C., Jan M., et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008, 111:5663-5671.
71. Díaz T., Navarro A., Ferrer G., et al. Lestaurtinib inhibition of the JAK/STAT signaling pathway in Hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One 2011, http://dx.doi.org/10.1371/journal.pone.0018856.
72. Sun S.M., Dijkstra M.K., Bijkerk A.C., et al. BAY 43-9006/sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br J Haematol 2011, 155:395-408.
73. Orlowski R.Z. The future of proteasome inhibitors in the relapsed/refractory multiple mieloma. Oncology 2011, 25:1-16.
74. Younes A., Pro B., Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006, 107:1731-1732.
75. Blum K.A., Johnson J.L., Niedzwieck D., et al. Single bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk Lymphoma 2007, 48:1313-1319.